'Immediately Practice-Changing' Lung Cancer Trial in Curative Setting
In a phase 3 trial, 92% of patients on Retevmo were cancer-free at two years, compared with 61% on placebo, investigators said.
- On Sunday, May 31, 2026, Eli Lilly and Company announced Phase 3 LIBRETTO-432 clinical trial results showing Retevmo reduced the risk of cancer recurrence or death by 83% in early-stage RET fusion-positive non-small cell lung cancer.
- Patients with early-stage RET fusion-positive lung cancer face high recurrence risk and have lacked a proven targeted treatment option, Dr. Jonathan Goldman, professor at the David Geffen School of Medicine at UCLA, explained during the American Society of Clinical Oncology Annual Meeting.
- The study showed 92% event-free survival at 2 years for selpercatinib versus 61% for placebo, with safety profiles remaining consistent with previous trials and Grade 3 or higher adverse events manageable through dose modification.
- Experts described the results as "immediately practice-changing," suggesting the therapy could become a new standard of care, according to David Spigel, ASCO-designated expert at the Sarah Cannon Research Institute, who was not involved in the study.
- Eli Lilly plans to submit these findings to global health authorities, while researchers emphasized that comprehensive biomarker testing at diagnosis is essential to ensure patients receive the most effective therapy for their specific genetic profile.
18 Articles
18 Articles
UCLA-Led Study Finds Promising Results for Lung Cancer Drug
A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows promising results for a drug that treats patients with a rare genetic type of early-stage lung cancer, researchers said Sunday. The study, funded by Eli Lilly and Company, indicated that the targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype of early-stage non-small cell l…
'Immediately Practice-Changing' Lung Cancer Trial in Curative Setting
(MedPage Today) -- CHICAGO -- The adjuvant treatment of RET fusion-positive non-small-cell lung cancer (NSCLC) following potentially curative surgery or radiotherapy has a new standard of care, researchers reported here. In a phase III study...
LoudounTimes.com
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the importance of comprehensive biomarker testing across all stages of disease
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
